You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 16, 2024

Claims for Patent: 10,493,035

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 10,493,035

Title:	Tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzald- ehyde
Abstract:	Provided herein are high strength/high drug load tablets comprising 2-hydroxy-6-((2-(1-isopropyl-1H-pyrazol-5-yl)pyridin-3-yl)methoxy)benzald- ehyde ("Compound 1"), dispersible tablets comprising Compound 1, processes of manufacturing such tablets, and methods for treating patients with the tablets. Compound 1 is useful for treating hematological disorders such as sickle cell disease, pulmonary disease such as idiopathic pulmonary fibrosis, and hypoxia and hypoxemia conditions.
Inventor(s):	Dalziel; Sean Mark (Burlingame, CA), Bejugam; Naveen (Santa Clara, CA), Habibizad; Nazila (San Mateo, CA), Komeyli; Ali (Pacifica, CA), Leung; DeMei (Los Altos, CA)
Assignee:	Global Blood Therapeutics, Inc. (South San Francisco, CA)
Application Number:	15/782,381
Patent Claims:	1. A tablet comprising: (i) about 50% to about 70% by weight of Compound 1 of formula: ##STR00002## (ii) about 30% to about 40% by weight of microcrystalline cellulose; (iii) about 0.25% to about 3% by weight of croscarmellose sodium; (iv) about 1% to about 5% by weight of magnesium stearate; (v) about 0.5% to about 2.5% of sodium lauryl sulfate; and (vi) about 0.25% to about 5% by weight of colloidal silicon dioxide; wherein the percentage by weight is relative to the total weight of the tablet. 2. The tablet of claim 1, comprising: (i) about 35% by weight of microcrystalline cellulose; (ii) about 1.25% by weight of croscarmellose sodium; (iii) about 2% by weight of magnesium stearate; and (iv) about 1.5% by weight of sodium lauryl sulfate. 3. The tablet of claim 1, wherein the tablet comprises from about 300 to about 900 mg of Compound 1. 4. The tablet of claim 1, comprising about 60% by weight of Compound 1. 5. The tablet of claim 1, comprising about 35% by weight of microcrystalline cellulose. 6. The tablet of claim 1, comprising about 1.25% by weight of croscarmellose sodium. 7. The tablet of claim 1, comprising about 2% magnesium stearate. 8. The tablet of claim 1, comprising about 1.5% of sodium lauryl sulfate. 9. The tablet of claim 1, wherein the tablet comprises from about 100 to about 600 mg of Compound 1.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.